HRT and TRT: Separating Evidence from Marketing

Hormone therapy for women and testosterone therapy for men both spent two decades under a cloud. For women, it was one scary headline. For men, it was FDA caution that newer research has mostly cleared up. Both now also have a wellness-marketing layer sitting on top of the real evidence, which makes it harder to tell what the science actually says versus what a clinic wants to sell you.

HRT: what the WHI scare actually found — and didn’t

In 2002, a major study called the Women’s Health Initiative made headlines with a scary-sounding claim: hormone therapy causes breast cancer and heart disease. That headline is still the thing most people remember, and it oversimplifies what the study actually showed. A later, deeper look at the full data found that the risk depends heavily on when a woman starts therapy relative to menopause.^[1] Women who started hormone therapy within 10 years of menopause, and under age 60, did not show the same higher heart risk seen in women who started a decade or more later — which was the group the original 2002 study leaned toward.

This is called the “timing hypothesis,” and it’s the piece that got lost in the original headline. It doesn’t mean HRT is risk-free. It means the real question is your age and how many years since menopause — not a blanket yes-or-no answer left over from a 20-year-old news cycle.

TRT: the FDA caution that newer research has narrowed

Testosterone replacement therapy carried a similar worry: that it might raise heart risk in men. A large study called the TRAVERSE trial tested this directly, following over 5,200 men with low testosterone who already had heart disease or were at high risk for it.^[2] Testosterone therapy performed no worse than a placebo for major heart problems — in exactly the group of men most likely to be harmed if the old worry were true. That’s a meaningfully different picture than the one behind the original FDA warning label.

“No worse than placebo” isn’t the same as “proven to help your heart,” though. This trial answered the safety question for serious heart events in a high-risk group. It doesn’t prove the broader energy and vitality claims that wellness clinics often attach to testosterone therapy.

Where marketing outruns the evidence

• “Bioidentical” doesn’t mean safer. The word just describes the molecule’s structure, not a different risk profile. Compounded “bioidentical” formulas also skip the dosing consistency and safety monitoring that FDA-regulated products go through.
• Hormone therapy isn’t an anti-aging protocol. Both bodies of evidence above are about managing symptoms and specific safety outcomes — not a general performance or longevity boost for people who don’t actually have a diagnosed deficiency.
• Skipping the diagnosis is a red flag. If a clinic offers therapy based on a single symptom checklist, without cycle tracking or repeat lab tests, they’re optimizing for a sale, not a real diagnosis.

The actual decision framework

For HRT, your age and years since your final period matter more than just “do I have symptoms” — that’s the variable the timing hypothesis is built on. For TRT, low testosterone should be confirmed with repeat morning labs plus real symptoms, following the same diagnostic standard covered in our testosterone-after-40 breakdown, before therapy is even on the table. In both cases, the real question isn’t “is this therapy good or bad.” It’s “does the evidence actually apply to someone with my age, timeline, and risk profile.” That’s a conversation for a clinician working from your real lab results — not a symptom quiz.

References

[1] Manson JE, et al. “Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials.” JAMA. 2013. DOI: 10.1001/jama.2013.278040. Finding: cardiovascular risk from hormone therapy is lower in women who start within 10 years of menopause and under age 60 (the “timing hypothesis”), versus those starting later. ↑︎

[2] Lincoff AM, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy.” New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2215025. Finding: in 5,246 hypogonadal men with existing/high cardiovascular risk, testosterone therapy was non-inferior to placebo for major adverse cardiac events. ↑︎

Kurt Greiner

Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.